-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Turning Point Therapeutics announced the latest results of its Phase 1/2 clinical trial of the precision therapy repotrectinib in the treatment of non-small cell lung cancer (NSCLC), and the latest results of the Phase 1 clinical trial of elzovantinib in the treatment of patients with non-small cell lung cancer and gastric cancer
.
Both precision therapies have shown promising anti-cancer activity
Repotrectinib is a potential "best-in-class" ROS1 and NTRK targeted inhibitor
.
It has a unique structure, the binding site with the target protein is located in the "ATP pocket", and is not affected by a variety of drug resistance mutations
▲Introduction to Repotrectinib (picture source: Turning Point Therapeutics official website)
The latest clinical trial results show that combining the data from phase 1 and phase 2 clinical trials (n=72), repotrectinib achieved a confirmed objective response rate (ORR) of 39% in patients with ROS1-positive advanced NSCLC
.
These patients had previously received platinum-containing chemotherapy and a pre-tyrosine kinase inhibitor (TKI) treatment
It is worth mentioning that in 18 patients with ROS1 resistance mutations, the confirmed ORR was 50%, and among patients with specific G2032R resistance mutations, the ORR was 53%, including two patients with complete remission
.
Shows the potential of repotrectinib to treat patients with drug-resistant ROS1-positive NSCLC
▲Efficacy data of Repotrectinib in NSCLC patients with ROS1 resistance mutations (picture source: Turning Point Therapeutics official website)
Elzovantinib (TPX-0022) is a powerful MET, SRC, and CSF1R inhibitor
.
Zai Lab has also obtained its exclusive license in Greater China
In the phase 1 clinical trial, a total of 54 patients with solid tumors carrying MET gene mutations received different doses of elzovantinib.
They included patients with solid tumors such as NSCLC, gastric cancer or gastroesophageal junction cancer, colorectal cancer, 93% of them Of patients have been treated with chemotherapy or immunotherapy
.
Preliminary results showed that among 11 NSCLC patients who had not received MET inhibitor treatment, the confirmed ORR was 36%
.
The duration of remission ranges from 1.
▲Efficacy results of Elzovantinib in NSCLC and gastric cancer patients who have not received MET inhibitor treatment (Image source: Turning Point Therapeutics official website)
Reference materials:
[1] Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates.
(The original text has been deleted)
